Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
- PMID: 24753132
- DOI: 10.1002/hep.27173
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
Abstract
Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity. The aim of this study was to determine whether the use of the SAF score and FLIP algorithm can decrease interobserver variations among pathologists. In a first session, pathologists categorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according to their own experience. In a second reading session, each pathologist reclassified the same slides by using the FLIP algorithm and SAF score, blinded to their first evaluation. The experiment was repeated with two different groups of pathologists at varying levels of training in liver pathology. The percentage of biopsy interpretation concordant with reference evaluation increased from 77% to 97% in Group 1 and from 42% to 75% in Group 2 after the use of the SAF score and FLIP algorithm. The strength of concordance in classification increased in Group 1 from moderate (κ = 0.54) to substantial (κ = 0.66) and from fair (κ = 0.35) to substantial (κ = 0.61) in Group 2 with application of the algorithm. With regard to the SAF score, concordance was substantial in Group 1 for steatosis (κ = 0.61), activity (κ = 0.75), and almost perfect for fibrosis (κ = 0.83 after pooling 1a, 1b, and 1c together into a single score F1). Similar trends were observed in Group 2 (κ = 0.54 for S, κ = 0.68 for A, and κ = 0.72 for F).
Conclusion: The FLIP algorithm based on the SAF score should decrease interobserver variations among pathologists and are likely to be implemented in pathology practice.
© 2014 by the American Association for the Study of Liver Diseases.
Similar articles
-
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.Hepatology. 2012 Nov;56(5):1751-9. doi: 10.1002/hep.25889. Hepatology. 2012. PMID: 22707395
-
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.J Hepatol. 2020 May;72(5):828-838. doi: 10.1016/j.jhep.2019.12.008. Epub 2019 Dec 17. J Hepatol. 2020. PMID: 31862486
-
Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.APMIS. 2017 Nov;125(11):962-973. doi: 10.1111/apm.12742. APMIS. 2017. PMID: 29076589
-
Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research.Semin Liver Dis. 2012 Feb;32(1):3-13. doi: 10.1055/s-0032-1306421. Epub 2012 Mar 13. Semin Liver Dis. 2012. PMID: 22418883 Review.
-
Histopathology, grading and staging of nonalcoholic fatty liver disease.Minerva Gastroenterol Dietol. 2018 Mar;64(1):28-38. doi: 10.23736/S1121-421X.17.02445-X. Epub 2017 Sep 25. Minerva Gastroenterol Dietol. 2018. PMID: 28948754 Review.
Cited by
-
Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice.Elife. 2024 Feb 27;12:RP87458. doi: 10.7554/eLife.87458. Elife. 2024. PMID: 38412016 Free PMC article.
-
Distinct changes in serum metabolites and lipid species in the onset and progression of NAFLD in Obese Chinese.Comput Struct Biotechnol J. 2024 Jan 20;23:791-800. doi: 10.1016/j.csbj.2024.01.007. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 38318437 Free PMC article.
-
Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD.JHEP Rep. 2023 Sep 25;6(2):100915. doi: 10.1016/j.jhepr.2023.100915. eCollection 2024 Feb. JHEP Rep. 2023. PMID: 38293684 Free PMC article.
-
Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review.Life (Basel). 2023 Oct 31;13(11):2144. doi: 10.3390/life13112144. Life (Basel). 2023. PMID: 38004284 Free PMC article. Review.
-
Evaluation of the efficacy of Biejia decoction pill combined with entecavir in the treatment of hepatitis B liver fibrosis/cirrhosis by VCTE.Sci Rep. 2023 Nov 10;13(1):19616. doi: 10.1038/s41598-023-46459-4. Sci Rep. 2023. PMID: 37949927 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical